Posted by Michael Wonder on 01 Mar 2024
SpringWorks Therapeutics announces EMA validation for marketing authorisation application of nirogacestat for the treatment of adults with desmoid tumours
29 February 2024 - Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in symptom burden including pain, physical and role functioning, and quality of life.
SpringWorks Therapeutics announced today that the EMA has validated the marketing authorisation application for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumours.
